New drug combo targets tough ovarian cancer

NCT ID NCT06617923

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer that has an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal cancer will take part. The goal is to see how well the combination works and what side effects occur.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian clear cell cancer ovarian endometrioid adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    RECRUITING

    Baltimore, Maryland, 21231-2410, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pennsylvania/Abramson Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••